X4 Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon
Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
Aug 12
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22CEO
X4 Pharmaceuticals has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | less than a year | no data | 0.099% $ 335.3k | |
| President & COO | less than a year | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Corporate Advisory Board | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| VP of Finance & Corporate Controller | 6.3yrs | no data | no data |
Experienced Management: XFOR's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chair | less than a year | no data | 0.099% $ 335.3k | |
| Founder & Member of Corporate Advisory Board | 9.8yrs | no data | no data | |
| Lead Independent Director | 7.5yrs | US$136.80k | 0.0046% $ 15.8k | |
| Independent Director | 6.8yrs | US$104.80k | 0.0037% $ 12.5k | |
| Member of Corporate Advisory Board | 9.8yrs | no data | no data | |
| Director | 6.8yrs | US$117.51k | 0.0073% $ 24.8k | |
| Independent Director | 4.3yrs | US$104.80k | 0.0037% $ 12.5k |
Experienced Board: XFOR's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 15:25 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |